Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Redhill Biophrma ADR (RDHL)

Redhill Biophrma ADR (RDHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,885
  • Shares Outstanding, K 1,281
  • Annual Sales, $ 6,530 K
  • Annual Income, $ 23,920 K
  • EBIT $ 9 M
  • EBITDA $ 15 M
  • 60-Month Beta 3.65
  • Price/Sales 1.61
  • Price/Cash Flow 0.02
  • Price/Book 159.52

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.34 +20.88%
on 11/20/24
8.75 -12.34%
on 12/02/24
-0.28 (-3.52%)
since 11/04/24
3-Month
6.34 +20.88%
on 11/20/24
12.50 -38.64%
on 09/10/24
-1.05 (-12.04%)
since 09/04/24
52-Week
6.34 +20.88%
on 11/20/24
48.75 -84.27%
on 12/05/23
-39.58 (-83.77%)
since 12/04/23

Most Recent Stories

More News
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on September...

RDHL : 7.67 (-0.65%)
RedHill Announces FDA sNDA Approval for Talicia®

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the U.S. Food and Drug...

RDHL : 7.67 (-0.65%)
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights

RHB-107 included in the U.S. Department of Defense-supported ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment; The...

RDHL : 7.67 (-0.65%)
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.

RedHill's partner, Gaelan Medical, part of the Ghassan Aboud Group (GAG), receives marketing approval from the United Arab Emirates (UAE) Ministry of Health...

RDHL : 7.67 (-0.65%)
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA

RHB-107 (upamostat) accepted for inclusion in ACESO's PROTECT adaptive platform trial for early COVID-19 outpatient treatment to be conducted in the U.S.,...

RDHL : 7.67 (-0.65%)
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed...

RDHL : 7.67 (-0.65%)
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered...

RDHL : 7.67 (-0.65%)
RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights

Q1/23 Talicia net revenues of $3.4 million; Cash balance of $28.8 million as of March 31, 2023[1]; Extinguishment of all debt obligations in exchange for the...

RDHL : 7.67 (-0.65%)
RedHill Provides R&D Update

RedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift...

RDHL : 7.67 (-0.65%)
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received...

RDHL : 7.67 (-0.65%)

Business Summary

RedHill Biopharma Ltd. is a specialty biopharmaceutical company, focused on gastrointestinal and infectious diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment is based in Raleigh, NC, and covers all areas relating...

See More

Key Turning Points

3rd Resistance Point 7.98
2nd Resistance Point 7.89
1st Resistance Point 7.78
Last Price 7.67
1st Support Level 7.58
2nd Support Level 7.49
3rd Support Level 7.38

See More

52-Week High 48.75
Fibonacci 61.8% 32.55
Fibonacci 50% 27.55
Fibonacci 38.2% 22.54
Last Price 7.67
52-Week Low 6.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar